Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Update on continued recovery efforts to mitigate shortages in Puerto Rico

    by
    • Optum Workers' Comp
    | Jan 05, 2018
    Tag Icon
    FDA
    The U.S. Food and Drug Administration (FDA) issued another update on the recovery efforts in Puerto Rico regarding the intravenous (IV) solution and medical device shortages that we have been following and providing updates about in our blogs.


  • New York Workers’ Comp. Board Proposes Pharmacy Formulary

    by
    • Optum Workers' Comp
    | Jan 04, 2018
    Tag Icon
    Formularies
    The New York State Workers’ Compensation Board has officially proposed rules to establish a prescription drug formulary in response to legislation passed earlier this year. That legislation required the Board to “establish” the formulary on or before December 31, 2017; however, the rules propose effective dates of July 1, 2018 for new prescriptions and December 31, 2018 for refill and renewal prescriptions, regardless of date of injury. Those dates may be adjusted further as a result of the rule-making process.


  • Shortage of injectable morphine products

    by
    • Optum Workers' Comp
    | Jan 03, 2018
    Tag Icon
    According to the U.S. Food and Drug Administration (FDA), morphine injection products have recently been in short supply. Morphine sulfate injection is an opioid analgesic made by several pharmaceutical manufacturers, including Fresenius Kabi USA, LLC, Pfizer (Hospira, Inc.), and West-Ward Pharmaceuticals, in a number of different strengths and formulations.


  • Update to medical device shortages manufactured in Puerto Rico

    by
    • Optum Workers' Comp
    | Dec 21, 2017
    Tag Icon
    FDA
    In October, we reported in our blog about the number of shortages of medical devices and drug products manufactured by facilities in Puerto Rico following the devastation and power outages from Hurricanes Irma and Maria. Recently, the U.S. Food and Drug Administration (FDA) provided an update on the situation. Though some power has been restored to the island and a handful of facilities have been able to stabilize production, many facilities continue to require the use of generators for power and have been unable to return to baseline production levels.